Sunil Healthcare Past Earnings Performance
Past criteria checks 0/6
Sunil Healthcare has been growing earnings at an average annual rate of 49.6%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been growing at an average rate of 9.1% per year.
Key information
49.6%
Earnings growth rate
49.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 9.1% |
| Return on equity | -2.8% |
| Net Margin | -1.7% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Sunil Healthcare makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 901 | -15 | 131 | 0 |
| 30 Sep 23 | 927 | -14 | 134 | 0 |
| 30 Jun 23 | 996 | 19 | 141 | 0 |
| 31 Mar 23 | 1,105 | 67 | 149 | 0 |
| 31 Dec 22 | 1,212 | 102 | 155 | 0 |
| 30 Sep 22 | 1,275 | 125 | 156 | 0 |
| 30 Jun 22 | 1,260 | 104 | 146 | 0 |
| 31 Mar 22 | 1,192 | 64 | 176 | 0 |
| 31 Dec 21 | 1,108 | 18 | 138 | 0 |
| 30 Sep 21 | 1,015 | -3 | 134 | 0 |
| 30 Jun 21 | 952 | -2 | 127 | 0 |
| 31 Mar 21 | 906 | -6 | 127 | 0 |
| 31 Dec 20 | 831 | -7 | 132 | 0 |
| 30 Sep 20 | 796 | -6 | 132 | 0 |
| 30 Jun 20 | 735 | -18 | 132 | 0 |
| 31 Mar 20 | 700 | -24 | 133 | 0 |
| 31 Dec 19 | 731 | -21 | 134 | 0 |
| 30 Sep 19 | 751 | -22 | 133 | 0 |
| 30 Jun 19 | 799 | -9 | 127 | 0 |
| 31 Mar 19 | 809 | -6 | 126 | 0 |
| 31 Mar 18 | 913 | 45 | 126 | 0 |
| 31 Mar 17 | 1,085 | 50 | 112 | 0 |
| 31 Dec 16 | 965 | 62 | 102 | 0 |
| 30 Sep 16 | 934 | 60 | 94 | 0 |
| 30 Jun 16 | 862 | 53 | 96 | 0 |
| 31 Mar 16 | 816 | 52 | 94 | 0 |
| 31 Dec 15 | 762 | 53 | 163 | 0 |
| 30 Sep 15 | 712 | 48 | 162 | 0 |
| 30 Jun 15 | 738 | 48 | 161 | 0 |
| 31 Mar 15 | 726 | 40 | 86 | 0 |
| 31 Dec 14 | 718 | 37 | 146 | 0 |
| 30 Sep 14 | 668 | 40 | 142 | 0 |
| 30 Jun 14 | 635 | 38 | 139 | 0 |
| 31 Mar 14 | 617 | 33 | 137 | 0 |
| 31 Dec 13 | 566 | 30 | 123 | 0 |
Quality Earnings: 537253 is currently unprofitable.
Growing Profit Margin: 537253 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 537253 is unprofitable, but has reduced losses over the past 5 years at a rate of 49.6% per year.
Accelerating Growth: Unable to compare 537253's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 537253 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (23.1%).
Return on Equity
High ROE: 537253 has a negative Return on Equity (-2.76%), as it is currently unprofitable.